Compound News and Research

RSS

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success.

16 Oct 2014

Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs).

15 Oct 2014

New method can reduce environmental impact caused by manufacturing processes

The human and environmental dangers posed by a widely used manufacturing technique could be almost eradicated thanks to research led by Plymouth University.

9 Oct 2014

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

9 Oct 2014

Researchers are developing compounds to combat causative agents of periodontitis

A total 12 million Germans suffer from periodontitis. If the inflammation remains untreated, this could lead to tooth loss. However, it is also suspected of triggering many other diseases, like cardiopulmonary diseases. Researchers are studying the interactions, and developing compounds to combat the causative agents.

9 Oct 2014

Shire receives FDA guidance on regulatory path for investigational compound SHP 465

Shire plc today announced that it has received further guidance from the U.S. Food and Drug Administration on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.

9 Oct 2014

AT2101 drug, evaluated for Gaucher disease, slows progression of Parkinson's disease in mice

A new study from UCLA found that a drug being evaluated to treat an entirely different disorder helped slow the progression of Parkinson's disease in mice.

9 Oct 2014

Researchers use computer based predictions to combat AIDS

The battle against AIDS cannot be won in the laboratory alone. To fight the potentially deadly virus that 34 million people are suffering from we need help from computers.

8 Oct 2014

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

For the second consecutive year, a Case Western Reserve University School of Medicine researcher has landed one of the year's much-coveted Director's New Innovator Awards from the National Institutes of Health. Principal investigator Rong Xu, PhD, assistant professor of medical informatics, will receive $2,377,000 for five years, starting immediately, to initiate computational analysis of thousands of drugs and their effects.

8 Oct 2014

Modified form of niclosamide drug may hold key to battling type 2 diabetes

Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease.

6 Oct 2014

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

30 Sep 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Seven NIH research contracts awarded to identify novel adjuvant candidates

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Spring Mountain Capital leads financing round for Oncoceutics with additional private investors' participation

Spring Mountain Capital, LP, a New York-based investment management firm, announced today that its private equity group structured and led a financing round for Oncoceutics, Inc. with additional private investors' participation.

29 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show.

29 Sep 2014

UCLA research may lead to novel treatment for PH1

Research by UCLA biochemists may lead to a new treatment - or even a cure - for PH1, a rare and potentially deadly genetic kidney disease that afflicts children. Their findings also may provide important insights into treatments for Parkinson's disease, Alzheimer's disease and other degenerative diseases.

27 Sep 2014

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

An interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research) has successfully developed a new strategy for reducing the often serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors).

26 Sep 2014

Anti-inflammatory treatment may prevent heterotopic ossification

An anti-inflammatory treatment, studied in the labs of regenerative medicine specialists and trauma surgeons, may prevent what's become one of the war-defining injuries for today's troops.

26 Sep 2014

Compound News and Research

Highland completes US$25 million offering of Class A Common Shares

Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

New method can reduce environmental impact caused by manufacturing processes

VAL-083 drug compound shows promise against non-small cell lung cancer

Researchers are developing compounds to combat causative agents of periodontitis

Shire receives FDA guidance on regulatory path for investigational compound SHP 465

AT2101 drug, evaluated for Gaucher disease, slows progression of Parkinson's disease in mice

Researchers use computer based predictions to combat AIDS

Case Western Reserve researcher lands Director's New Innovator Awards from NIH

Modified form of niclosamide drug may hold key to battling type 2 diabetes

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Seven NIH research contracts awarded to identify novel adjuvant candidates

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Spring Mountain Capital leads financing round for Oncoceutics with additional private investors' participation

Aptose joins Beat AML research collaboration

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

UCLA research may lead to novel treatment for PH1

Researchers develop new strategy for reducing serious side effects of modern anticancer drugs

Anti-inflammatory treatment may prevent heterotopic ossification

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News